Titlebook: Biomarkers in Breast Cancer; Giampietro Gasparini,Daniel F. Hayes Book 2006 Humana Press 2006 DNA.classification.gene expression.systemic

釋放

滔滔不絕地說(shuō)

舊病復(fù)發(fā)

-B2 as a Therapeutic Target in combination with chemotherapy in the treatment of metastatic, HER2 overexpressing breast cancer. This chapter reviews the history of the development of trastuzumab including the biology of HER signaling, the technical issues of antibody “humanization,” the diagnostic challenges in developing “ta

詩(shī)集

五行打油詩(shī)

Occult Metastatic Cells in Breast Cancer Patientsnow be assessed in cancer patients using immunocytochemical and molecular assays able to detect even single metastatic cells. However, careful validation of technically confounding variables, including choice of detection antibody, preparation of cellular samples, and size of analyzed sample volumes

經(jīng)典

Circulating HER2/neu, specifically directed to the extracellular domain (ECD) of the HER2/neu oncoprotein. The HER2/neu ECD is shed from cancer cells into the circulation and is measurable by immunoassay. We performed an in-depth review of the peer-reviewed literature on circulating ECD levels with respect to prevalenc

聯(lián)合

不怕任性

Book 2006or receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.

付出

https://doi.org/10.1007/978-3-322-85805-4formation. This chapter addresses some of these issues and presents initial analytical validation procedures of newly developed biomarker assays, the validation of already established assay procedures for routine use on a day-to-day basis, and finally discusses some aspects on adequate (external) quality control proficiency testing.

歌曲